Evonik Invests US$100 Million to Enhance U.S. Manufacturing Site

Evonik Industries AG announced a US$100 million investment to modernize its Lafayette, Indiana facility. This development aims to meet the escalating demand for U.S.-based contract development and manufacturing services. The investment will span five years, focusing on upgrading key equipment including 100 m³ reactors to enhance automation and efficiency. Supported by local government, this move strengthens Evonik's strategic commitment to the U.S. market.

The Tippecanoe site is crucial in Evonik's plan to balance its global assets, with a focus on North America. The investment is part of Next Generation Technologies to maintain technological leadership and energy efficiency. The site is one of the world's largest for active pharmaceutical ingredients, with significant capacity for high-potency APIs and other complex drug substances.

Geopolitical uncertainties highlight the need for Western production sites. With increasing complexity in active pharmaceutical ingredients, Evonik's investment aims to support challenging molecules essential for critical medical conditions.